Clinical trials: Meningitis, Bacterial
Meningococcal Meningitis
Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)
To assess the immunogenicity of Novartis (formerly Chiron) Meningococcal ACWY conjugate vaccine (MenACWY) when administered as a two-dose schedule at 6 and 12 months of age.
- Trial name
- NCT00310856
- Testing
- MenACWY-CRM, MenC-CRM, DTaP-Hib-IPV
- Where
- 3 sites in Canada
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningitis, Meningococcal
Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants
Infant phase: To determine the safety of and production of antibodies by a group C meningococcal conjugate vaccine (MnCC), when given at 2, 3, and 4 months of age with routine vaccines.
- Trial name
- NCT00314041
- Testing
- Meningococcal C, DTP/Hib
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infections, Meningococcal
Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
The purpose/aim of this study is to assess the safety and antibody response to vaccination with a booster dose of Menveo given 4-6 years after primary MenACWY vaccination and to assess the safety and antibody response to a single…
- Trial name
- NCT02986854
- Testing
- Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 704 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease, Meningococcal Meningitis
Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents
The purpose of this phase 2 study is to evaluate the safety, tolerability and immunogenicity of two doses of 4 different investigational MenABCWY combination vaccine when administered to healthy adolescents aged 11-18 years.
- Trial name
- NCT01210885
- Testing
- Meningococcal Vaccine
- Where
- 8 sites in Chile, Colombia and 1 more
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Infections
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Safety immune response of Novartis MenACWY-CRM conjugate vaccine when given to healthy toddlers
- Trial name
- NCT00626327
- Testing
- MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
- Where
- 90 sites in United States
- Volunteers
- 1,630 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningitis, Meningococcal Disease
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
This aim of the study is to assess post-marketing safety of a single dose of Menactra® vaccine with the intent to support conversion from monitored release to initial registration of Menactra® vaccine in the Philippines.
- Trial name
- NCT01270503
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 127 sites in Philippines
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcemia
Immunology and Safety of Menactra® in Children in Saudi Arabia
This study will be conducted among children in Saudi Arabia who previously received two doses of A, C, Y, W-135 polysaccharide vaccine before the age of 2 years, and in meningococcal vaccine-naïve children (Control Group).
- Trial name
- NCT00539032
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcal
A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents
The purpose of this study is to evaluate the safety and immunogenicity of an investigational meningococcal B rLP2086 vaccine in adolescents aged 11 to 18 years old.
- Trial name
- NCT00808028
- Testing
- meningococcal B rLP2086 vaccine.
- Where
- 27 sites in Australia, Poland and 1 more
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningococcal Disease, Meningococcal Meningitis
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines
This study will evaluate safety, tolerability, and immunogenicity of a booster dose of a meningococcal vaccine formulation in adolescents.
- Trial name
- NCT01367158
- Testing
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Tdap
- Where
- 7 sites in Chile, Colombia and 1 more
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningitis, Meningococcal
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants.
- Trial name
- NCT00474526
- Testing
- Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib
- Where
- 63 sites in United States, Argentina and 1 more
- Volunteers
- 4,545 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Bacterial Meningitis, Neonatal Infection
Neonatal Bacterial Meningitis Cohort
Neonatal bacterial meningitis (BM) is a devastating infection that occurs more commonly in neonates than in any other age group, and is associated with significant morbidity and mortality, especially in developing countries.
- Trial name
- NCT03499652
- Testing
- neonatal bacterial meningitis risk score
- Where
- 2 sites in China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Epidemic Meningitis
Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)
The purpose of this clinical study is to evaluate the immunogenicity and immunopersistence of the ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector).The protocol consists of two parts: Part 1 enrolled 660…
- Trial name
- NCT05935176
- Testing
- MCV4
- Where
- China
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.